Vault-13

Sands Capital Alternatives, LLC

ARLINGTON, VA · CIK 1846444 · 13F filing filed 2026-08-13

SEC-registered investment adviser since 2011 · limited liability company

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
Arlington, VA (main office)United States United Statesabout 60
Fitzrovia LondonUnited Kingdom United Kingdom2
San Francisco, CAUnited States United States2
New York City, NYUnited States United States1
San Juan, PRUnited States United States1
SingaporeSingapore Singapore

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$613.5m reported value +45.7% vs Q1 2026
24positions
80.8%in top 10
3 new 10 added 2 reduced 0 sold out vs Q1 2026

Holdings, Q2 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 ALAMAR BIOSCIENCES INC COMMON STOCK ALMR ALMR 4,230,926 $114.6m18.68% 18.68% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 4.2m
2 NU HLDGS LTD ORD SHS CL A NU NU 7,094,952 $94.8m15.45% 15.45% AddedShares held: Q3 2025 7.2m, Q4 2025 6.9m, Q1 2026 6.5m, Q2 2026 7.1m +557.2k +557,183 8.5%
3 KLAVIYO INC COM SER A KVYO KVYO 3,928,146 $59.3m9.67% 9.67% AddedShares held: Q3 2025 3.5m, Q4 2025 3.6m, Q1 2026 3.6m, Q2 2026 3.9m +278.5k +278,468 7.6%
4 BETA BIONICS INC COM BBNX BBNX 3,708,043 $58.1m9.47% 9.47% UnchangedShares held: Q3 2025 3.6m, Q4 2025 3.6m, Q1 2026 3.7m, Q2 2026 3.7m
5 SPYGLASS PHARMA INC COM SHS SGP SGP 2,500,012 $55.7m9.07% 9.07% UnchangedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 2.5m, Q2 2026 2.5m
6 INHIBIKASE THERAPEUTICS INC COM NEW IKT IKT 13,018,965 $26.4m4.31% 4.31% UnchangedShares held: Q3 2025 10.9m, Q4 2025 13.0m, Q1 2026 13.0m, Q2 2026 13.0m
7 DOORDASH INC CL A DASH DASH 127,562 $23.5m3.84% 3.84% AddedShares held: Q3 2025 90.1k, Q4 2025 95.6k, Q1 2026 111.2k, Q2 2026 127.6k +16.3k +16,331 14.7%
8 COUPANG INC CL A CPNG CPNG 1,329,314 $23.1m3.76% 3.76% AddedShares held: Q3 2025 795.0k, Q4 2025 870.4k, Q1 2026 1.0m, Q2 2026 1.3m +317.2k +317,223 31.3%
9 DATADOG INC CL A COM DDOG DDOG 80,851 $21.1m3.43% 3.43% ReducedShares held: Q3 2025 118.7k, Q4 2025 85.8k, Q1 2026 85.8k, Q2 2026 80.9k -4.9k -4,942 -5.8%
10 BIOAGE LABS INC COM BIOA BIOA 786,353 $19.3m3.14% 3.14% UnchangedShares held: Q3 2025 786.4k, Q4 2025 786.4k, Q1 2026 786.4k, Q2 2026 786.4k
11 10X GENOMICS INC CL A COM TXG TXG 481,770 $18.5m3.01% 3.01% UnchangedShares held: Q3 2025 481.8k, Q4 2025 481.8k, Q1 2026 481.8k, Q2 2026 481.8k
12 SAMSARA INC COM CL A IOT IOT 515,658 $16.7m2.73% 2.73% ReducedShares held: Q3 2025 598.9k, Q4 2025 466.2k, Q1 2026 560.3k, Q2 2026 515.7k -44.6k -44,629 -8.0%
13 ODYSSEY THERAPEUTICS INC COMMON STOCK ODTX ODTX 875,000 $16.4m2.67% 2.67% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 875.0k
14 TOAST INC CL A TOST TOST 364,879 $10.2m1.65% 1.65% AddedShares held: Q3 2025 156.6k, Q4 2025 301.6k, Q1 2026 301.6k, Q2 2026 364.9k +63.2k +63,232 21.0%
15 ACUMEN PHARMACEUTICALS INC COM ABOS ABOS 3,720,105 $9.9m1.62% 1.62% UnchangedShares held: Q3 2025 3.4m, Q4 2025 3.4m, Q1 2026 3.7m, Q2 2026 3.7m
16 SERVICETITAN INC SHS CL A TTAN TTAN 108,545 $7.7m1.25% 1.25% AddedShares held: Q3 2025 0, Q4 2025 89.9k, Q1 2026 89.9k, Q2 2026 108.5k +18.7k +18,689 20.8%
17 CEREBRAS SYSTEMS INC COM CL A CBRS CBRS 32,825 $7.3m1.18% 1.18% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 32.8k
18 SNOWFLAKE INC CL A SNOW SNOW 24,498 $6.2m1.02% 1.02% AddedShares held: Q3 2025 27.0k, Q4 2025 20.3k, Q1 2026 20.3k, Q2 2026 24.5k +4.2k +4,245 21.0%
19 MONDAY COM LTD SHS MNDY MNDY 81,982 $5.9m0.97% 0.97% AddedShares held: Q3 2025 58.3k, Q4 2025 67.9k, Q1 2026 67.9k, Q2 2026 82.0k +14.1k +14,114 20.8%
20 TARSUS PHARMACEUTICALS INC COM TARS TARS 85,000 $5.3m0.87% 0.87% UnchangedShares held: Q3 2025 170.0k, Q4 2025 85.0k, Q1 2026 85.0k, Q2 2026 85.0k
21 TAYSHA GENE THERAPIES INC COM SHS TSHA TSHA 724,873 $4.9m0.80% 0.80% UnchangedShares held: Q3 2025 724.9k, Q4 2025 724.9k, Q1 2026 724.9k, Q2 2026 724.9k
22 CANDEL THERAPEUTICS INC COM CADL CADL 405,837 $4.2m0.68% 0.68% UnchangedShares held: Q3 2025 405.8k, Q4 2025 405.8k, Q1 2026 405.8k, Q2 2026 405.8k
23 ACRIVON THERAPEUTICS INC COMMON STOCK ACRV ACRV 2,289,271 $4.1m0.66% 0.66% AddedShares held: Q3 2025 2.1m, Q4 2025 2.1m, Q1 2026 2.1m, Q2 2026 2.3m +166.7k +166,666 7.8%
24 FIGMA INC CLASS A COM STK FIG FIG 22,165 $401.0k0.07% 0.07% AddedShares held: Q3 2025 18.3k, Q4 2025 18.3k, Q1 2026 18.3k, Q2 2026 22.2k +3.9k +3,879 21.2%

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
ACUMEN PHARMACEUTICALS INC ABOS · 13G · filed 2025-08-13 ABOS 5.6%≈ $9.1m 13G 2025-08-13